Maze Therapeutics, Inc. (MAZE)
| Market Cap | 1.53B +22.1% |
| Revenue (ttm) | 20.00M +700.0% |
| Net Income | -133.59M |
| EPS | -2.52 |
| Shares Out | 55.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 539,300 |
| Open | 26.59 |
| Previous Close | 26.23 |
| Day's Range | 26.46 - 28.11 |
| 52-Week Range | 21.95 - 53.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 61.50 (+123.8%) |
| Est. Earnings | Nov 5, 2026 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $61.5, which is an increase of 123.80% from the latest price.
News
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research support...
Maze Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $50 price target The firm sees the company’s APOL1-mediated kidney disease assets driving upside over the medium term.
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
Maze Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and a pivotal trial planned. Initial results show strong efficacy across patient subgroups, and biomarker strategies are being explored. The PKU program is also progressing with promising early data.
Maze Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
Three precision medicine programs are advancing, with lead candidate MZE829 showing promising phase II results in AMKD and a pivotal trial planned for 2027. MZE782, a novel SLC6A19 inhibitor, is in phase II for PKU, with strong phase I data and top-line results expected in 2027.
Maze Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Three clinical programs are advancing, with MZE829 showing promising phase II results in AMKD and broad potential across patient subgroups. Key data readouts and trial initiations are expected over the next two years, supported by strong financial resources and ongoing industry collaboration.
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pat...
Maze Therapeutics Announces Appointments to Its Board of Directors
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience
Maze Therapeutics reports Q2 EPS (76c), consensus (70c)
“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in…
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data e...
Maze Therapeutics Earnings release: Q2 2026
Maze Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Maze Therapeutics Quarterly report: Q2 2026
Maze Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Maze Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
MZE829 showed robust efficacy and safety in phase II for APOL1 kidney disease, with pivotal studies planned for 2027 and full data expected by 2026/2027. MZE782 demonstrated best-in-class potential for PKU, with phase II data due in 2027. Cash runway extends through 2029.
Maze Therapeutics Transcript: AGM 2026
The meeting featured the election of two directors and ratification of the auditor, both approved by majority vote. No shareholder questions were submitted, and final results will be filed with the SEC.
Maze Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The presentation highlighted progress in developing small molecule therapies for renal and metabolic diseases, with lead programs MZE829 and MZE782 advancing through clinical trials. Strong financials support a runway into 2029, enabling multiple data catalysts and pivotal studies in APOL1 kidney disease and PKU.
Maze Therapeutics Slides: Investor presentation
Maze Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patie...
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of…
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 202...
Maze Therapeutics Earnings release: Q1 2026
Maze Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Maze Therapeutics Quarterly report: Q1 2026
Maze Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Maze Therapeutics Proxy statement: Proxy filing
Maze Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Maze Therapeutics Proxy statement: Proxy filing
Maze Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50
The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based health...
Maze Therapeutics Slides: Corporate presentation
Maze Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.